RNA m(6)A Methylation Regulators Subclassify Luminal Subtype in Breast Cancer.
RNA m(6)A Methylation Regulators Subclassify Luminal Subtype in Breast Cancer.
复制标题
DOI：
10.3389/fonc.2020.611191
复制
发表时间：
2020
影响因子：
4.7
通讯作者：
Tong WM
中科院分区：
文献类型：
--
作者：
Yang L;Wu S;Ma C;Song S;Jin F;Niu Y;Tong WM
RNA N6-methyladenosine (m6A) methylation is the most prevalent epitranscriptomic modification in mammals, with a complex and fine-tuning regulatory system. Recent studies have illuminated the potential of m6A regulators in clinical applications including diagnosis, therapeutics, and prognosis. Based on six datasets of breast cancer in The Cancer Genome Atlas (TCGA) database and two additional proteomic datasets, we provide a comprehensive view of all the known m6A regulators in their gene expression, copy number variations (CNVs), DNA methylation status, and protein levels in breast tumors and their association with prognosis. Among four breast cancer subtypes, basal-like subtype exhibits distinct expression and genomic alteration in m6A regulators from other subtypes. Accordingly, four representative regulators (IGF2BP2, IGF2BP3, YTHDC2, and RBM15) are identified as basal-like subtype-featured genes. Notably, luminal A/B samples are subclassified into two clusters based on the methylation status of those four genes. In line with its similarity to basal-like subtype, cluster1 shows upregulation in immune-related genes and cell adhesion molecules, as well as an increased number of tumor-infiltrating lymphocytes. Besides, cluster1 has worse disease-free and progression-free survival, especially among patients diagnosed with stage II and luminal B subtype. Together, this study highlights the potential functions of m6A regulators in the occurrence and malignancy progression of breast cancer. Given the heterogeneity within luminal subtype and high risk of recurrence and metastasis in a portion of patients, the prognostic stratification of luminal A/B subtypes utilizing basal-featured m6A regulators may help to improve the accuracy of diagnosis and therapeutics of breast cancer.
登录
查看更多内容
影响因子：
46.9
作者：
Ball, Madeleine P.;Li, Jin Billy;Gao, Yuan;Lee, Je-Hyuk;LeProust, Emily M.;Park, In-Hyun;Xie, Bin;Daley, George Q.;Church, George M.
通讯作者：
Church, George M.
DOI：
10.1186/s13058-017-0812-y
发表时间：
2017-03-29
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Aure MR;Vitelli V;Jernström S;Kumar S;Krohn M;Due EU;Haukaas TH;Leivonen SK;Vollan HK;Lüders T;Rødland E;Vaske CJ;Zhao W;Møller EK;Nord S;Giskeødegård GF;Bathen TF;Caldas C;Tramm T;Alsner J;Overgaard J;Geisler J;Bukholm IR;Naume B;Schlichting E;Sauer T;Mills GB;Kåresen R;Mælandsmo GM;Lingjærde OC;Frigessi A;Kristensen VN;Børresen-Dale AL;Sahlberg KK;OSBREAC
通讯作者：
OSBREAC
影响因子：
3.8
作者：
Ciriello, Giovanni;Sinha, Rileen;Hoadley, Katherine A.;Jacobsen, Anders S.;Reva, Boris;Perou, Charles M.;Sander, Chris;Schultz, Nikolaus
通讯作者：
Schultz, Nikolaus
胰腺癌中 m6A 相关基因和 m6A RNA 甲基化调节因子的鉴定及其与生存的关系
影响因子：
--
作者：
Geng, Yan;Guan, Renguo;Hou, Baohua
通讯作者：
Hou, Baohua
影响因子：
5.2
作者：
Huang, Guang-Zhao;Wu, Qing-Qing;Lv, Xiao-Zhi
通讯作者：
Lv, Xiao-Zhi